Core Viewpoint - Enovix Corporation (ENVX) shows significant potential for upside, with a mean price target of $20.89 indicating an 81.5% increase from its current trading price of $11.51 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $6.09, suggesting variability in analyst predictions [2] - The lowest estimate is $12.00, indicating a 4.3% increase, while the highest estimate is $30.00, suggesting a potential surge of 160.6% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about ENVX's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 1.5% rise in the Zacks Consensus Estimate [12] - ENVX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, and reliance solely on them may lead to poor investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - 4D Molecular Therapeutics, Inc. (FDMT) has shown significant stock price appreciation of 42.1% over the past four weeks, with a mean price target of $31.13 suggesting a potential upside of 208.5% from the current price of $10.09 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $8.37, indicating variability among analysts [2] - The lowest price target of $16.00 suggests a 58.6% increase, while the highest target of $40.00 indicates a potential surge of 296.4% [2] - A low standard deviation among price targets reflects a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about FDMT's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - Over the last 30 days, one earnings estimate has increased, leading to a 0.6% rise in the Zacks Consensus Estimate [12] - FDMT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]

Core Viewpoint - Red Robin (RRGB) shows potential for significant upside, with a mean price target of $11 indicating a 61.1% upside from the current price of $6.83 [1] Price Targets and Estimates - The average price target for RRGB ranges from a low of $6.00 to a high of $15.00, with a standard deviation of $3.74, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 12.2%, while the highest indicates a potential upside of 119.6% [2] - Analysts' agreement on earnings estimates is strong, which supports the view of potential upside [4][11] Analyst Behavior and Price Target Reliability - Solely relying on consensus price targets for investment decisions may not be wise due to historical inaccuracies in predictions [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding price movement direction [9] Earnings Estimates and Stock Potential - Recent revisions in earnings estimates have shown a positive trend, with the Zacks Consensus Estimate for the current year increasing by 19.5% over the past month [12] - RRGB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [13] - The correlation between earnings estimate revisions and stock price movements supports the expectation of an upside for RRGB [11] Conclusion on Price Movement - While consensus price targets may not reliably indicate the extent of potential gains, they can provide a useful guide for understanding price movement direction [14]

Shares of Exodus Movement, Inc. (EXOD) have gained 2.7% over the past four weeks to close the last trading session at $28.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $56.86 indicates a potential upside of 98.5%.The average comprises seven short-term price targets ranging from a low of $45.00 to a high of $70.00, with a standard deviation of $8.99. While the lowest estima ...

Core Viewpoint - DarioHealth Corp. (DRIO) has seen a significant price increase of 124% over the past four weeks, with analysts suggesting further upside potential based on a mean price target of $21.33, indicating a 42.8% increase from the current price of $14.94 [1]. Price Targets and Analyst Consensus - The average price target for DRIO ranges from a low of $12.00 to a high of $27.00, with a standard deviation of $8.14, indicating variability in analyst estimates. The lowest estimate suggests a potential decline of 19.7%, while the highest points to an upside of 80.7% [2]. - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about DRIO's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the past 30 days, one estimate for DRIO has increased, leading to a 9.7% rise in the Zacks Consensus Estimate for the current year [12]. - DRIO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13]. Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions. Analysts may set overly optimistic targets due to business incentives, which can inflate expectations [3][8][10].

Core Viewpoint - Priority Technology (PRTH) shows potential for significant upside, with a mean price target of $12.6 indicating a 64.7% increase from its current price of $7.65 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $2.3, suggesting variability in analyst predictions [2] - The lowest estimate of $10.00 indicates a 30.7% increase, while the highest estimate of $16.00 suggests a 109.2% increase [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.9%, with one estimate moving higher and no negative revisions [12] - PRTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, and reliance solely on them may lead to poor investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

分组1 - Mission Produce, Inc. (AVO) closed at $11.76, with a 0.2% gain over the past four weeks, and a mean price target of $17.33 indicates a 47.4% upside potential [1] - The average price targets range from a low of $17.00 to a high of $18.00, with a standard deviation of $0.58, suggesting a 44.6% to 53.1% upside from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] 分组2 - The Zacks Consensus Estimate for the current year has increased by 15.7% over the last 30 days, with no negative revisions [12] - AVO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of AVO's potential gains, it does suggest a positive price movement direction [14]

Core Viewpoint - MBX Biosciences, Inc. (MBX) has shown significant stock price appreciation of 54.6% over the past four weeks, with a mean price target of $60.29 indicating a potential upside of 280.1% from the current price of $15.86 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $18.94, where the lowest estimate of $30.00 suggests an 89.2% increase, and the highest estimate of $84.00 indicates a potential surge of 429.6% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about MBX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 2.7% rise in the Zacks Consensus Estimate for the current year [12] - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While the consensus price target is often sought after, it is important to approach it with skepticism, as empirical research indicates that price targets can mislead investors [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - UBS has set a price target of $255 for Assurant, indicating a potential upside of approximately 17.9% from the current stock price of $216.29 [1] Group 1: Financial Performance - Assurant is set to announce its third-quarter financial results on November 4, 2025, after market close, with a conference call scheduled for the following morning [2] - The upcoming financial results are expected to influence the stock's performance and investor sentiment [2] Group 2: Stock Performance - Currently, Assurant's stock price is $216.29, reflecting a decrease of $5.40 or approximately -2.44% [3] - The stock has traded between $216.21 and $223.65 today, with a yearly high of $230.55 and a low of $174.97, indicating volatility [3] Group 3: Market Capitalization - Assurant's market capitalization is approximately $10.91 billion, with a trading volume of 365,113 shares on the NYSE, reflecting the company's size and investor interest [4] - The upcoming financial results could impact the market capitalization and trading volume depending on the company's performance [4]

Core Viewpoint - Lakeland Industries (LAKE) shows significant upside potential with a mean price target of $24.25, indicating a 63.9% increase from the current price of $14.8 [1] Price Targets - The average price target consists of four estimates ranging from a low of $20.00 to a high of $27.00, with a standard deviation of $3.1, suggesting a consensus among analysts [2] - The lowest estimate indicates a 35.1% increase, while the highest suggests an 82.4% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on LAKE's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has been correlated with near-term stock price movements, reinforcing the optimistic outlook [11] Earnings Estimates - Over the past 30 days, one earnings estimate has increased, leading to a Zacks Consensus Estimate rise of 177.8% [12] - LAKE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of LAKE's potential gains, it does provide a useful guide for price movement direction [14]